研究者業績
  1. 研究者検索結果一覧
  2. 大宮 直木

大宮 直木

オオミヤ ナオキ  (Naoki Ohmiya)

基本情報

所属
藤田医科大学 医学部 医学科 先端光学診療学講座
学位
博士(医学）
J-GLOBAL ID
200901011108502975
researchmap会員ID
6000005568
患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。

研究キーワード

 8

研究分野

 1

委員歴

 28
もっとみる

受賞

 4

論文

 270
  • Takako Tsukamoto, Yohei Iwata, Naoki Ohmiya, Kazumitu Sugiura
    The Journal of dermatology 2024年9月30日  査読有り
  • Edouard Louis, Stefan Schreiber, Remo Panaccione, Peter Bossuyt, Luc Biedermann, Jean-Frederic Colombel, Gareth Parkes, Laurent Peyrin-Biroulet, Geert D’Haens, Tadakazu Hisamatsu, Britta Siegmund, Kaichun Wu, Brigid S. Boland, Gil Y. Melmed, Alessandro Armuzzi, Phillip Levine, Jasmina Kalabic, Su Chen, Ling Cheng, Lei Shu, W. Rachel Duan, Valerie Pivorunas, Yuri Sanchez Gonzalez, Ronilda D’Cunha, Ezequiel Neimark, Kori Wallace, Raja Atreya, Marc Ferrante, Edward V. Loftus, Domingo Balderramo, Silvina Goncalves, Juan Lasa, Abel Novillo, Orlando Ruffinengo, Sonja Heeren, Walter Reinisch, Filip Baert, Peter Bossuyt, Arnaud Colard, Olivier Dewit, Marc Ferrante, Denis Franchimont, Edouard Louis, Jean-Francois Rahier, Carlos Francesconi, Roberto Kaiser Junior, Rogerio Parra, Ligia Sassaki, Plamen Penchev, Desislav Stanchev, Kenneth Atkinson, Melanie Beaton, Talat Bessissow, Susan Greenbloom, Jean-Rene Lachance, Allen Lim, Remo Panaccione, Jean- Michel Samson, Scott Shulman, Jesse Siffledeen, Ignacio Alfaro, Carlos Valenzuela, Gustavo Walsen, Ping An, Qian Cao, Yan Chen, Youxiang Chen, Xiang Gao, Xiaohua Hou, Naizhong Hu, YAN Li, Fei Liu, Mei Liu, Lu Lungen, Zhihua Ran, Tongyu Tang, Xin Wang, Shaoqi Yang, Qiang Zhan, Guoxin Zhang, Hu Zhang, Jie Zhang, Xiaolan Zhang, Jie Zhong, Xiaoping Zou, Eligio Alvarez, Juan Ricaurte, Vladimir Borzan, Zeljko Krznaric, Zeljko Puljiz, Martin Bortlik, Pavel Svoboda, Jan Ulbrych, Tomas Vanasek, Jens Kjeldsen, Lars Munck, Anja Poulsen, Ezzat Ali, Osama Salem, Hisham Sawah, Imam Waked, Romain Altwegg, Mathurin FLAMANT, Mathurin Fumery, Xavier Hebuterne, David Laharie, Laurent Peyrin-Biroulet, Xavier Roblin, Xavier Treton, Raja Atreya, Herbert Deppe, Peter Hasselblatt, Arne Kandulski, Jochen Klaus, Thomas Krause, Torsten Kucharzik, Jessica Mertens, Michael Mross, Axel Naumann, Wolfgang Reindl, Ingolf Schiefke, Stefan Schreiber, Stefan Schubert, Britta Siegmund, Andreas Sturm, Georgios Bamias, Ioannis Koutroubakis, Spilios Manolakopoulos, Gerassimos Mantzaris, Maria Tzouvala, Irit Avni-Biron, Eran Goldin, Lior Katz, Adi Lahat-Zok, Arik Segal, Sandro Ardizzone, Alessandro Armuzzi, Michele Cicala, Antonio Colecchia, Rocco Cosintino, Antonio Gasbarrini, Andrea Geccherle, Edoardo Giovanni Giannini, Paolo Gionchetti, Francesco Luzza, Giovanni Monteleone, Antonino Privitera, Simone Saibeni, Marcello Vangeli, Yasuhiko Abe, Nobuo Aoyama, Kunio Asonuma, Yutaka Endo, Motohiro Esaki, Toshimitsu Fujii, Katsuyuki Fukuda, Fumihito Hirai, Yasuhiro Hisanaga, Noriyuki Horiki, Mikitaka Iguchi, Keisuke Ishigami, Yoh Ishiguro, Hiroaki Ito, Yoichi Kakuta, Koji Kamikozuru, Jun Kato, Teruki Kawanishi, Taku Kobayashi, Hiroyuki Kuge, Atsuo Maemoto, Tomoyuki Masuda, Katsuyoshi Matsuoka, Kayoko Matsushima, Masashi Matsushima, Satoshi Motoya, Katsuhiko Nakai, Koichi Nakajima, Masanao Nakamura, Atsushi Nishida, Takahiro Nishikawa, Nobuaki Nishimata, Toshiaki Ochiai, Naoki Ohmiya, Yoshifumi Ohnishi, Shiro Oka, Keiji Ozeki, Daisuke Saito, Masayuki Saruta, Makoto Sasaki, Masahito Shimizu, Ken Sugimoto, Tomohisa Sujino, Takayoshi Suzuki, Hajime Takatori, Noritaka Takatsu, Hidetoshi Takedatsu, Ken Takeuchi, Hiroki Tanaka, Satoki Tokito, Tatsuya Toyokawa, Yoshito Uenoyama, Takatsugu Yamamoto, Takayuki Yamamoto, Hiroshi Yasuda, Kaoru Yokoyama, Aleksejs Derovs, Aldis Pukitis, Laimas Jonaitis, Edita Kazenaite, Lourdes Lol-be Pinzon Te, Geert D'Haens, Maurice Lutgens, James Brooker, Richard Gearry, Ben Griffiths, Stephen Inns, Michael Schultz, Jerzy Eszyk, Jaroslaw Kierkus, Dariusz Kleczkowski, Adam Kopon, Robert Petryka, Jaroslaw Regula, Tomasz Romanczyk, Grazyna Rydzewska-Wyszkowska, Piotr Sikorski, Michal Talarek, Rute Cerqueira, Tiago Goncalves, Susana Lopes, Paula Ministro, Francisco Portela, Helena Tavares, Mihai-Mircea Diculescu, Adrian Goldis, Andrada Seicean, Alina Agafina, Anton Edin, Evgenia Gerasimova, Maryana Gettueva, Vladimir Kashnikov, Vladimir Rafalskiy, Ksenia Sharapova, Elena Smolyarchuk, Daria Varganova, Sasa Grgov, Igor Jovanovic, Petar Svorcan, Dino Tarabar, Khoon Lin Ling, Jozef Balaz, Juraj Durina, Milos Gregus, Martin Laclav, David Drobne, Eduan Deetlefs, Jonny Peter, Muhammad Rajabally, Jennifer Rosa, Jan van Zyl, John Wright, Jae Hee Cheon, Byung Ik Jang, Sang-Bum Kang, Dukhwan Kim, Tae Oh Kim, Young-Ho Kim, Jonghun Lee, Kang-Moon Lee, Dong Il Park, Geun Am Song, Luisa Castro Laria, Ana Echarri Piudo, Santiago Garcia Lopez, Vincent Hernandez Ramirez, Maria Dolores Martin Arranz, Pilar Varela Trastoy, Maria Vera Mendoza, Mikael Lordal, Luc Biedermann, Benjamin Misselwitz, Chung-Hsin Chang, Jen-Wei Chou, Chia-Jung Kuo, Ching-Pin Lin, Chia-Hung Tu, Huseyin Alkim, Yusuf Erzin, Irfan Soykan, Tetiana Kravchenko, Nataliia Tsarynna, Vira Vyshyvanyuk, Tariq Ahmad, Fraser Cummings, Kapil Kapur, Arthur Kaser, Alexandra Kent, Gareth Parkes, Kamal Patel, Richard Speight, Alan Steel, Faten Aberra, Humberto Aguilar, Badr Al Bawardy, Ashwin Ananthakrishnan, Matthew Barnes, Kendall Beck, Charles Berkelhammer, Brigid Boland, Jeff Bullock, Adeeti Chiplunker, Robin Dalal, Sushila Dalal, Belkis Delgado, Michael DiGiovanna, George Aaron DuVall, Curtis Freedland, Keith Friedenberg, Philip Ginsburg, Tarek Hassanein, Peter Higgins, John Hong, Jason Hou, Vivek Huilgol, Nikhil Inamdar, Saurabh Kapur, David Kerman, Henry Levine, Nilesh Lodhia, Edward Loftus, Jaime Mayoral, Donald McNeil, Gil Melmed, Andria Mushahwar, Harry Ojeas, Bhaktasharan Patel, Raymond Phillips, Joe Pouzar, Harry Sarles Jr., Joel Schock, Shahriar Sedghi, Nirav Shah, Junaid Siddiqui, David Stokesberry, Le-Chu Su, Arun Swaminath, Dharmendra Verma, John Weber, Ziad Younes, Timothy Zisman
    JAMA 2024年7月22日  査読有り
    Importance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective To evaluate the efficacy and safety of risankizumab when administered as an induction and a maintenance therapy for patients with ulcerative colitis. Design, Setting, and Participants Two phase 3 randomized clinical trials were conducted. The induction trial was conducted at 261 clinical centers (in 41 countries) and enrolled 977 patients from November 5, 2020, to August 4, 2022 (final follow-up on May 16, 2023). The maintenance trial was conducted at 238 clinical centers (in 37 countries) and enrolled 754 patients from August 28, 2018, to March 30, 2022 (final follow-up on April 11, 2023). Eligible patients had moderately to severely active ulcerative colitis; a history of intolerance or inadequate response to 1 or more conventional therapies, advanced therapies, or both types of therapies; and no prior exposure to risankizumab. Interventions For the induction trial, patients were randomized 2:1 to receive 1200 mg of risankizumab or placebo administered intravenously at weeks 0, 4, and 8. For the maintenance trial, patients with a clinical response (determined using the adapted Mayo score) after intravenous treatment with risankizumab were randomized 1:1:1 to receive subcutaneous treatment with 180 mg or 360 mg of risankizumab or placebo (no longer receiving risankizumab) every 8 weeks for 52 weeks. Main Outcomes and Measures The primary outcome was clinical remission (stool frequency score ≤1 and not greater than baseline, rectal bleeding score of 0, and endoscopic subscore ≤1 without friability) at week 12 for the induction trial and at week 52 for the maintenance trial. Results Among the 975 patients analyzed in the induction trial (aged 42.1 [SD, 13.8] years; 586/973 [60.1%] were male; and 677 [69.6%] were White), the clinical remission rates at week 12 were 132/650 (20.3%) for 1200 mg of risankizumab and 20/325 (6.2%) for placebo (adjusted between-group difference, 14.0% [95% CI, 10.0%-18.0%], P < .001). Among the 548 patients analyzed in the maintenance trial (aged 40.9 [SD, 14.0] years; 313 [57.1%] were male; and 407 [74.3%] were White), the clinical remission rates at week 52 were 72/179 (40.2%) for 180 mg of risankizumab, 70/186 (37.6%) for 360 mg of risankizumab, and 46/183 (25.1%) for placebo (adjusted between-group difference for 180 mg of risankizumab vs placebo, 16.3% [97.5% CI, 6.1%-26.6%], P < .001; adjusted between-group difference for 360 mg of risankizumab vs placebo, 14.2% [97.5% CI, 4.0%-24.5%], P = .002). No adverse event signals were detected in the treatment groups. Conclusion and Relevance Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis. Further study is needed to identify benefits beyond the 52-week follow-up. Trial Registration ClinicalTrials.gov Identifiers: NCT03398148 and NCT03398135
  • Tomomitsu Tahara, Noriyuki Horiguchi, Hyuga Yamada, Tsuyoshi Terada, Dai Yoshida, Masaaki Okubo, Kohei Funasaka, Yoshihito Nakagawa, Tomoyuki Shibata, Naoki Ohmiya
    Journal of gastrointestinal and liver diseases : JGLD 33(2) 164-169 2024年6月29日  査読有り
    BACKGROUND AND AIMS: Early gastric cancers (EGCs) after Helicobacter pylori (H. pylori) eradication often appear as reddish depressed lesions (RDLs); the same features are also appeared in benign stomachs after eradication. We compared clinic-pathological and endoscopic features of benign and neoplastic RDLs after H. pylori eradication. METHODS: 228 neoplastic RDLs after H. pylori eradication were studied. All lesions were divided into neoplastic RDLs (differentiated carcinoma or adenoma, n=114) and benign RDLs (n=114) according to the histology. Clinical and pathological characteristics were compared in neoplastic and benign groups. Endoscopic diagnostic yields using the white light (WL) endoscopy, chromoendoscopy (CE) using indigo carmine dye and the magnifying endoscopy with narrow-band imaging (ME-NBI) were also evaluated in relation to the pathological diagnosis. RESULTS: Size of neoplastic RDLs was larger than that of benign RDLs (p<0.01). Sensitivity, specificity and accuracy for predicting pathological types of RDLs was 70.1%, 52.6% and 61.4% for the WL, 65.8%, 63.1% and 65.4% for the CE, while the ME-NBI scored better with the 88.6%, 88.6%, 99.1% and 93.9% of sensitivity, specificity and accuracy. The accuracy of the ME-NBI was 99.9% (113/114) in the benign RDLs and 89.4% (101/114) for the neoplastic RDLs. Undiagnosed neoplastic RDLs using the ME-NBI were associated with more differentiated tumors such as adenoma and well-differentiated adenocarcinoma (tub1) and the presence of an unclear demarcation line. CONCLUSIONS: ME-NBI is useful to diagnose RDLs after H. pylori eradiation, while some of neoplastic lesions are difficult to diagnose using the ME-NBI.
  • Ken Yamashita, Shiro Oka, Takeshi Yamada, Keigo Mitsui, Hironori Yamamoto, Keiichi Takahashi, Akio Shiomi, Kinichi Hotta, Yoji Takeuchi, Toshio Kuwai, Fumio Ishida, Shin-Ei Kudo, Shoichi Saito, Masashi Ueno, Eiji Sunami, Tomoki Yamano, Michio Itabashi, Kazuo Ohtsuka, Yusuke Kinugasa, Takayuki Matsumoto, Tamotsu Sugai, Toshio Uraoka, Koichi Kurahara, Shigeki Yamaguchi, Tomohiro Kato, Masazumi Okajima, Hiroshi Kashida, Yoshito Akagi, Hiroaki Ikematsu, Masaaki Ito, Motohiro Esaki, Masaya Kawai, Takashi Yao, Madoka Hamada, Takahiro Horimatsu, Keiji Koda, Yasumori Fukai, Koji Komori, Yusuke Saitoh, Yukihide Kanemitsu, Hiroyuki Takamaru, Kazutaka Yamada, Hiroaki Nozawa, Tetsuji Takayama, Kazutomo Togashi, Eiji Shinto, Takehiro Torisu, Akira Toyoshima, Naoki Ohmiya, Takeshi Kato, Eigo Otsuji, Shinji Nagata, Yojiro Hashiguchi, Kenichi Sugihara, Yoichi Ajioka, Shinji Tanaka
    Journal of gastroenterology 59(5) 376-388 2024年5月  査読有り
    BACKGROUND: The clinicopathological features and prognosis of primary small bowel adenocarcinoma (PSBA), excluding duodenal cancer, remain undetermined due to its rarity in Japan. METHODS: We analyzed 354 patients with 358 PSBAs, between January 2008 and December 2017, at 44 institutions affiliated with the Japanese Society for Cancer of the Colon and Rectum. RESULTS: The median age was 67 years (218 males, 61.6%). The average tumor size was 49.9 (7-100) mm. PSBA sites consisted of jejunum (66.2%) and ileum (30.4%). A total of 219 patients (61.9%) underwent diagnostic small bowel endoscopy, including single-balloon endoscopy, double-balloon endoscopy, and capsule endoscopy before treatment. Nineteen patients (5.4%) had Lynch syndrome, and 272 patients (76.8%) had symptoms at the initial diagnosis. The rates for stages 0, I, II, III, and IV were 5.4%, 2.5%, 27.1%, 26.0%, and 35.6%, respectively. The 5-year overall survival rates at each stage were 92.3%, 60.0%, 75.9%, 61.4%, and 25.5%, respectively, and the 5-year disease-specific survival (DSS) rates were 100%, 75.0%, 84.1%, 59.3%, and 25.6%, respectively. Patients with the PSBA located in the jejunum, with symptoms at the initial diagnosis or advanced clinical stage had a worse prognosis. However, multivariate analysis using Cox-hazard model revealed that clinical stage was the only significant predictor of DSS for patients with PSBA. CONCLUSIONS: Of the patients with PSBA, 76.8% had symptoms at the initial diagnosis, which were often detected at an advanced stage. Detection during the early stages of PSBA is important to ensure a good prognosis.
  • 堀口 徳之, 大宮 直木, 舩坂 好平, 長坂 光夫, 大野 栄三郎, 中川 義仁, 葛谷 貞二, 宮原 良二, 柴田 知行, 廣岡 芳樹
    日本消化器病学会雑誌 121(臨増総会) A190-A190 2024年3月  
もっとみる

MISC

 1258
  • 中村 陽介, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 平松 武, 杉本 啓之, 鷲見 肇, 舩坂 好平, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A756-A756 2012年9月  
  • 杉本 啓之, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 陽介, 平松 武, 鷲見 肇, 舩坂 好平, 中村 正直, 宮原 良二, 大宮 直木, 鈴木 美穂, 木村 宏之, 尾崎 紀夫, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A763-A763 2012年9月  
  • 鷲見 肇, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 陽介, 平松 武, 杉本 啓之, 舩坂 好平, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A764-A764 2012年9月  
  • 舩坂 好平, 宮原 良二, 古川 和宏, 鶴留 一誠, 山本 富美子, 松崎 一平, 大野 栄三郎, 中村 正直, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 渡辺 修, 前田 修, 安藤 貴文, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A778-A778 2012年9月  
  • 前田 修, 安藤 貴文, 大宮 直木, 石黒 和博, 渡辺 修, 宮原 良二, 舩坂 好平, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A793-A793 2012年9月  
  • 古川 和宏, 宮原 良二, 舩坂 好平, 鶴留 一誠, 山本 富美子, 松崎 一平, 大野 栄三郎, 中村 正直, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 前田 修, 渡辺 修, 安藤 貴文, 森 健策, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A798-A798 2012年9月  
  • 名倉 明日香, 大宮 直木, 中村 正直, 水谷 太郎, 山村 健史, 石原 誠, 山田 弘志, 舩坂 好平, 大野 栄三郎, 宮原 良二, 川嶋 啓揮, 伊藤 彰浩, 廣岡 芳樹, 渡辺 修, 安藤 貴文, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A809-A809 2012年9月  
  • 石原 誠, 大宮 直木, 中村 正直, 水谷 太郎, 山村 健史, 山田 弘志, 名倉 明日香, 舩坂 好平, 大野 栄三郎, 宮原 良二, 川嶋 啓揮, 伊藤 彰浩, 廣岡 芳樹, 渡辺 修, 安藤 貴文, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A810-A810 2012年9月  
  • 三村 俊哉, 安藤 貴文, 石黒 和博, 前田 修, 渡辺 修, 神谷 徹, 氏原 正樹, 平山 裕, 森瀬 和宏, 船坂 好平, 宮原 良二, 大宮 直木, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A817-A817 2012年9月  
  • 神谷 徹, 安藤 貴文, 石黒 和博, 前田 修, 渡辺 修, 三村 俊哉, 氏原 正樹, 平山 裕, 森瀬 和宏, 船坂 好平, 宮原 良二, 大宮 直木, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A834-A834 2012年9月  
  • 渡辺 修, 安藤 貴文, 石黒 和博, 前田 修, 神谷 徹, 三村 俊哉, 氏原 正樹, 平山 裕, 森瀬 和宏, 舩坂 好平, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    日本消化器病学会雑誌 109(臨増大会) A837-A837 2012年9月  
  • 大宮 直木, 中村 正直, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.2) 2667-2667 2012年9月  
  • 山田 弘志, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.2) 2758-2758 2012年9月  
  • 山本 富美子, 宮原 良二, 舩坂 好平, 古川 和宏, 鶴留 一誠, 松崎 一平, 大野 栄三郎, 中村 正直, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 渡辺 修, 前田 修, 安藤 貴文, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.2) 2830-2830 2012年9月  
  • 森瀬 和宏, 安藤 貴文, 石黒 和博, 前田 修, 渡辺 修, 神谷 徹, 三村 俊哉, 氏原 正樹, 平山 裕, 舩坂 好平, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.2) 2844-2844 2012年9月  
  • 松崎 一平, 宮原 良二, 舩坂 好平, 古川 和宏, 鶴留 一誠, 山本 富美子, 大野 栄三郎, 中村 正直, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 渡辺 修, 前田 修, 安藤 貴文, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.2) 2870-2870 2012年9月  
  • Takuya Ishikawa, Akihiro Itoh, Hiroki Kawashima, Eizaburo Ohno, Hiroshi Matsubara, Yuya Itoh, Yosuke Nakamura, Takeshi Hiramatsu, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto, Yoshiki Hirooka
    World journal of gastroenterology 18(29) 3883-8 2012年8月7日  査読有り
    AIM: To investigate the usefulness of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the differentiation of autoimmune pancreatitis (AIP). METHODS: We retrospectively reviewed 47 of 56 AIP patients who underwent EUS-FNA and met the Asian diagnostic criteria. On 47 EUS-FNA specimens, we evaluated the presence of adequate material and characteristic features of lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct-centric pancreatitis (IDCP) mentioned in the International Consensus Diagnostic Criteria and examined if these findings make a contribution to the differential diagnosis of type 1 and type 2 AIR A disposable 22-gauge needle was used for EUS-FNA. RESULTS: Adequate specimens including pancreatic tissue for differentiating AIP from cancer were obtained from 43 of 47 patients who underwent EUS-FNA. EUS-FNA was performed from the pancreatic head in 21 cases, which is known to be technically difficult when performed by core biopsy; there was no significant difference in the results compared with pancreatic body-tail. Nine of 47 patients met level 1 findings of LPSP and 5 patients met level 2 findings of LPSP. No one met level 1 findings of IDCP, but 3 patients met level 2 findings of IDCP. Of 10 seronegative cases, 2 cases were diagnosed with "definitive type 1 AIP," and 3 cases were diagnosed with "probable type 2 AIP" when considering both the level 2 histological findings and response to steroids. CONCLUSION: EUS-FNA is useful in the differentiation of type 1 and type 2 AIP, particularly in seronegative cases. (C) 2012 Baishideng. All rights reserved.
  • 杉本 啓之, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 陽介, 平松 武, 鷲見 肇, 大宮 直木, 宮原 良二, 中村 正直, 後藤 秀実
    肝胆膵治療研究会誌 10(1) 108-108 2012年8月  
  • 平松 武, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 陽介, 杉本 啓之, 鷲見 肇, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    肝胆膵治療研究会誌 10(1) 125-125 2012年8月  
  • Hiroyuki Takenaka, Naoki Ohmiya, Yoshiki Hirooka, Masanao Nakamura, Eizaburo Ohno, Ryoji Miyahara, Hiroki Kawashima, Akihiro Itoh, Osamu Watanabe, Takafumi Ando, Hidemi Goto
    Journal of clinical gastroenterology 46(7) 575-80 2012年8月  査読有り
    Objectives: Protein-losing enteropathy (PLE) is often difficult to diagnose. We evaluated the diagnostic yields of underlying diseases of PLE among esophagogastroduodenoscopy, colonoscopy, fluoroscopic conventional enteroclysis (FCE), videocapsule endoscopy (VCE), and double-balloon enteroscopy (DBE) and prognosis after treatment. Methods: Between June 2003 and August 2010, 25 consecutive patients with PLE confirmed by fecal alpha 1-antitrypsin clearance (n = 18) and technetium 99m human serum albumin scintigraphy (n = 19) were enrolled, investigated, and treated. Results: Of 25 patients, 4 (16%) with intestinal lymphangiectasia secondary to macroglobulinemia (n = 1), amyloidosis (n = 2), and strongyloidiasis (n = 1) were diagnosed at preceding esophagogastroduodenoscopy or colonoscopy, and 7 (32%) with primary intestinal lymphangiectasia and chronic nonspecific multiple ulcers unrelated to nonsteroidal anti-inflammatory drugs of the small intestine were newly diagnosed at FCE or VCE. Other 11 (44%) patients with primary intestinal lymphangiectasia, small-bowel tumors, amyloidosis, chronic nonspecific multiple ulcers unrelated to nonsteroidal anti-inflammatory drugs of the small intestine, Crohn's disease, and small-bowel ulcers due to polyarteritis nodosa were diagnosed only at DBE with biopsy. Three patients with primary intestinal lymphangiectasia, cirrhosis after living donor liver transplantation, and congestive heart failure were not diagnosed at any small-bowel examination. The overall diagnostic yield of FCE, VCE, and DBE was 62% (8/13), 83% (14/17), and 88% (22/25), respectively. Eight patients (32%) died of underlying disorders regardless of medical treatment over the follow-up period. Conclusions: DBE with pathologic findings of biopsy specimens was useful for the differential diagnosis of PLE. Noninvasive VCE might be preferable and useful for screening and follow up of PLE without stricture. Prognosis of a subgroup of PLE was poor regardless of treatment.
  • Eizaburo Ohno, Akihiro Itoh, Hiroki Kawashima, Takuya Ishikawa, Hiroshi Matsubara, Yuya Itoh, Yosuke Nakamura, Takeshi Hiramatsu, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Masatoshi Ishigami, Yoshiaki Katano, Hidemi Goto, Yoshiki Hirooka
    Pancreas 41(6) 855-62 2012年8月  査読有り
    Objectives: The natural history of branch duct-type intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas remains unclear. We conducted a retrospective long-term follow-up study for malignant transformation (MT) of BD-IPMNs focusing on morphological changes. Methods: The subjects consisted of 142 patients who underwent contrast-enhanced endoscopic ultrasonography for initial diagnosis from January 2001 with more than 12 months of follow-up. The MT rate, including the co-occurrence of invasive ductal cancer, was evaluated by univariate and multivariate analysis. In addition, on the basis of morphological changes in patients who underwent surgery, the predictive factors for malignant IPMNs were evaluated. Results: Median follow-up term was 42.5 months (range, 12-105 months). Thirty patients who exhibited morphological changes underwent surgery. Malignant transformation occurred in 9 patients (6.3%), and 5-year MT rate was 10.7%. The co-occurrence of invasive ductal cancer was seen in 5 patients. Multivariate analysis showed that the existence of mural nodules at initial diagnosis and involvement of main pancreatic duct were significant predictors of MT of BD-IPMN. Conclusions: Malignant transformation of BD-IPMN is not rare. The observation of morphological changes of main pancreatic duct and nodules, mainly on contrast-enhanced endoscopic ultrasonography, is practical and useful for predicting MT of BD-IPMN itself.
  • Wataru Honda, Naoki Ohmiya, Yoshiki Hirooka, Masanao Nakamura, Ryoji Miyahara, Eizaburo Ohno, Hiroki Kawashima, Akihiro Itoh, Osamu Watanabe, Takafumi Ando, Hidemi Goto
    Gastrointestinal endoscopy 76(2) 344-54 2012年8月  査読有り
    Background: Small-bowel tumors (SBTs) represent a diagnostic challenge. Objective: To evaluate the usefulness of contrast-enhanced CT (CECT), fluoroscopic enteroclysis (FE), video-capsule endoscopy (VCE), and double-balloon endoscopy (DBE) and the outcome after treatment. Design: Single-center, retrospective study. Setting: Tertiary-care referral hospital. Patients: Between June 2003 and May 2011, 159 consecutive patients with SBTs (93 malignant and 66 benign) were enrolled. Main Outcome Measurements: Comparison of diagnostic yields among CECT, FE, VCE, and DBE and the prognosis. Results: CECT and FE had significantly lower diagnostic yields of SBTs &lt;= 10 mm, but VCE and DBE had high yields of SBTs regardless of size. CECT had a significantly lower diagnostic yield of epithelial tumors compared with subepithelial tumors. When stratified by the site, the diagnostic yield of VCE for SBTs located only in the distal duodenum/the proximal jejunum (73%) was significantly lower than that for SBTs located in other areas (90%). Comparisons among the 4 methods revealed that VCE and DBE had significantly higher diagnostic yields than CECT, and DBE had significantly higher diagnostic yields than VCE, but a combination of CECT and VCE had a diagnostic yield similar to that of DBE. The histologic diagnostic yield of SBTs by DBE was 92%, and 25% of SBTs were enteroscopically treated. Metastatic tumors had the poorest overall survival, followed by adenocarcinomas and malignant lymphomas. Limitations: Retrospective comparative study. Conclusion: For the detection of SBTs, a combination screening method by using VCE and CECT is recommended. DBE is useful for histologic diagnosis and endoscopic treatment. (Gastrointest Endosc 2012;76:344-54.)
  • 大宮 直木, 廣岡 芳樹, 中村 正直, 宮原 良二, 伊藤 彰浩, 渡辺 修, 安藤 貴文, 後藤 秀実
    Modern Physician 32(7) 882-885 2012年7月  
    ＜ポイント＞●Peutz-Jeghers症候群の合併症は前期合併症(ポリープによる腸重積・出血・腹痛)と後期合併症(悪性腫瘍の発生)に分けられる。●カプセル内視鏡(VCE)、ダブルバルーン内視鏡(DBE)、小腸X線(経管法)による小腸ポリープ数の比較試験では小腸X線と比較し、VCE、DBEの検出能は優れており、さらにVCEはDBEに比し全小腸観察率が高かった。●DBE下小腸ポリープ摘除は有効かつ低侵襲である。●小腸ポリープの病理学的検索では20mm以下のポリープの腺腫合併率は1.5%、20mmを越えるポリープの腺腫・腺癌の合併率は26.7%と有意差があり、腫瘍、腸重積の合併は15mm以上のポリープに認められた。●小腸ポリープ増殖能の規定因子は小腸、大腸ポリープ数であり、ポリープ摘除後のフォローアップは小腸、大腸ポリープ数を勘案して半年〜4年毎にカプセル内視鏡で行うのがよいと思われた。(著者抄録)
  • 西前 香寿, 上原 圭介, 吉岡 裕一郎, 江畑 智希, 横山 幸浩, 大宮 直木, 中村 正直, 後藤 秀実, 梛野 正人
    日本消化器外科学会総会 67回 2-2 2012年7月  
  • Masanao Nakamura, Naoki Ohmiya, Ryoji Miyahara, Takafumi Ando, Osamu Watanabe, Hiroki Kawashima, Akihiro Itoh, Yoshiki Hirooka, Hidemi Goto
    HEPATO-GASTROENTEROLOGY 59(117) 1474-1477 2012年7月  査読有り
    Backgrounds/Aims: Flexible spectral imaging color enhancement (FICE) is an image enhancement system that can obtain bright and high-contrast images. FICE for capsule endoscopy (CE) is available during interpretation of Given Imaging, but its usefulness is rarely reported. The aim of this study is to evaluate the preview of angiodysplasia by FICE in comparison with the conventional preview. Methodology: The accumulated CE data of 50 patients with angiodysplasia were randomly assigned to 2 equally sized groups of conventional reading and FICE reading. One experienced doctor analyzed them for the first time in a quick-view mode and the mean reading time, sensitivity and specificity for detecting angiodysplasia by each method were evaluated for comparisons including suspected blood indicator. Results: The mean reading time was 14min for both conventional reading and FICE reading. The two previews of angiodysplasia were significantly superior to the function of suspected blood indicator (p&lt;0.01). The sensitivity and specificity of conventional reading for detecting angiodysplasia were 80% and 100%, respectively. Those of FICE reading were 91% and 86%, respectively. FICE reading was superior in term of sensitivity, while it resulted in more false-positive lesion findings and lower specificity. However, such false-positive findings by FICE reading can be correctly identified at a glance by converting the image to conventional mode. Conclusions: This study demonstrates that FICE enables accurate detection of angiodysplasia in the preview of CE.
  • Yasuo Kakugawa, Yutaka Saito, Shoichi Saito, Kenji Watanabe, Naoki Ohmiya, Mitsuyuki Murano, Shiro Oka, Tetsuo Arakawa, Hidemi Goto, Kazuhide Higuchi, Shinji Tanaka, Hideki Ishikawa, Hisao Tajiri
    World journal of gastroenterology 18(17) 2092-8 2012年5月7日  査読有り
    AIM: To evaluate the effectiveness of our proposed bowel preparation method for colon capsule endoscopy. METHODS: A pilot, multicenter, randomized controlled trial compared our proposed "reduced volume method" (group A) with the "conventional volume method" (group B) preparation regimens. Group A did not drink polyethylene glycol electrolyte lavage solution (PEG-ELS) the day before the capsule procedure, while group B drank 2 L. During the procedure day, groups A and B drank 2 L and 1 L of PEG-ELS, respectively, and swallowed the colon capsule (PillCam COLON (R) capsule). Two hours later the first booster of 100 g magnesium citrate mixed with 900 mL water was administered to both groups, and the second booster was administered six hours post capsule ingestion as long as the capsule had not been excreted by that time. Capsule videos were reviewed for grading of cleansing level. RESULTS: Sixty-four subjects were enrolled, with results from 60 analyzed. Groups A and B included 31 and 29 subjects, respectively. Twenty-nine (94%) subjects in group A and 25 (86%) subjects in group B had adequate bowel preparation (ns). Twenty-two (71%) of the 31 subjects in group A excreted the capsule within its battery life compared to 16 (55%) of the 29 subjects in group B (ns). Of the remaining 22 subjects whose capsules were not excreted within the battery life, all of the capsules reached the left side colon before they stopped functioning. A single adverse event was reported in one subject who had mild symptoms of nausea and vomiting one hour after starting to drink PEG-ELS, due to ingesting the PEG-ELS faster than recommended. CONCLUSION: Our proposed reduced volume bowel preparation method for colon capsule without PEG-ELS during the days before the procedure was as effective as the conventional volume method. (C) 2012 Baishideng. All rights reserved.
  • Yuya Itoh, Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Eizaburo Ohno, Yosuke Nakamura, Takeshi Hiramatsu, Hiroyuki Sugimoto, Hajime Sumi, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto
    GASTROENTEROLOGY 142(5) S850-S850 2012年5月  
  • 竹中 宏之, 大宮 直木, 中村 正直, 大野 栄三郎, 川嶋 啓揮, 宮原 良二, 伊藤 彰浩, 廣岡 芳樹, 渡辺 修, 安藤 貴文, 松浦 哲生, 清水 裕子, 黒岩 正憲, 森田 敬一, 後藤 秀実
    消化器内科 54(5) 529-533 2012年5月  
    2003年10月〜2011年2月に著者らが経験した小腸潰瘍性病変215例の特徴と小腸画像検査の診断能について検討した。その結果、1)小腸潰瘍性病変の検査契機は原因不明の消化管出血(OGIB)や腸閉塞、クローン病の小腸精査が大半を占め、原因疾患の内訳は若年層と高齢層で異なっていた。2)小腸画像検査の診断能はダブルバルーン内視鏡(DBE)が85.1%、カプセル内視鏡(VCE)が51.7%、ゾンデ式小腸造影検査(FE)が50.0%で、DBEがVCE、FEと比べ診断能が優れていた。しかし、DBEはVCE、FEに比べ侵襲が大きく、検査施行にマンパワーも必要であった。3)今回の検討では小腸画像検査のみでは診断に難渋する症例もあり、診断的治療や経過観察によって診断がつく症例もみられた。また経過を追っても診断のつかない、分類不能の小腸潰瘍もあり、更なる症例の集積による診断、治療の確立が重要と考えられた。
  • Kenji Watanabe, Naoki Ohmiya, Masanao Nakamura, Yasuhiro Fujiwara, Hidemi Goto, Tetsuo Arakawa
    GASTROINTESTINAL ENDOSCOPY 75(4) 371-371 2012年4月  
  • Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Eizaburo Ohno, Yuya Itoh, Yosuke Nakamura, Hiroyuki Sugimoto, Hajime Sumi, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 184-184 2012年4月  
  • Hiroki Kawashima, Akihiro Itoh, Eizaburo Ohno, Yuya Itoh, Yosuke Nakamura, Takeshi Hiramatsu, Hiroyuki Sugimoto, Hajime Sumi, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto, Yoshiki Hirooka
    GASTROINTESTINAL ENDOSCOPY 75(4) 396-396 2012年4月  
  • Naoki Ohmiya, Yoshiki Hirooka, Wataru Honda, Masanao Nakamura, Kei Ohara, Makoto Ishihara, Koji Yamada, Asuka Nagura, Eizaburo Ohno, Hiroki Kawashima, Ryoji Miyahara, Akihiro Itoh, Osamu Watanabe, Takafumi Ando, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 249-249 2012年4月  
  • Issei Tsurudome, Ryoji Miyahara, Kohei Funasaka, Kazuhiro Furukawa, Keiichi Sakamaki, Hidezumi Tatematsu, Fumiko Yamamoto, Ippei Matsuzaki, Eizaburo Ohno, Hiroki Kawashima, Akihiro Itoh, Naoki Ohmiya, Yoshiki Hirooka, Osamu Watanabe, Osamu Maeda, Takafumi Ando, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 366-366 2012年4月  
  • Koji Yamada, Naoki Ohmiya, Asuka Nagura, Makoto Ishihara, Kei Ohara, Eizaburo Ohno, Hiroki Kawashima, Ryoji Miyahara, Akihiro Itoh, Yoshiki Hirooka, Osamu Watanabe, Takafumi Ando, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 251-251 2012年4月  
  • Takeshi Hiramatsu, Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Eizaburo Ohno, Yuya Itoh, Yosuke Nakamura, Hiroyuki Sugimoto, Hajime Sumi, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 309-309 2012年4月  
  • Yosuke Nakamura, Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Eizaburo Ohno, Yuya Itoh, Takeshi Hiramatsu, Hajime Sumi, Hiroyuki Sugimoto, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 248-249 2012年4月  
  • Makoto Ishihara, Naoki Ohmiya, Kei Ohara, Koji Yamada, Asuka Nagura, Ryoji Miyahara, Osamu Watanabe, Takafumi Ando, Eizaburo Ohno, Hiroki Kawashima, Akihiro Itoh, Yoshiki Hirooka, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 250-250 2012年4月  
  • 伊藤 裕也, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 中村 陽介, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    超音波医学 39(Suppl.) S257-S257 2012年4月  
  • 中村 陽介, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    超音波医学 39(Suppl.) S411-S411 2012年4月  
  • 鷲見 肇, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 正直, 宮原 良二, 大宮 直木, 後藤 秀実
    超音波医学 39(Suppl.) S424-S424 2012年4月  
  • 大宮 直木, 中村 正直, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 884-884 2012年4月  
  • 名倉 明日香, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 924-924 2012年4月  
  • 山田 弘志, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 992-992 2012年4月  
  • 石原 誠, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 1015-1015 2012年4月  
  • 平松 武, 廣岡 芳樹, 伊藤 彰浩, 川嶋 啓揮, 大野 栄三郎, 伊藤 裕也, 中村 陽介, 杉本 啓之, 鷲見 肇, 宮原 良二, 大宮 直木
    Gastroenterological Endoscopy 54(Suppl.1) 1091-1091 2012年4月  
  • 坂巻 慶一, 宮原 良二, 舩坂 好平, 古川 和宏, 立松 英純, 鶴留 一誠, 山本 富美子, 松崎 一平, 大野 栄三郎, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 渡辺 修, 前田 修, 安藤 貴文, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 1154-1154 2012年4月  
  • 渡辺 修, 安藤 貴文, 石黒 和博, 前田 修, 日比 知志, 神谷 徹, 三村 俊哉, 氏原 正樹, 平山 裕, 森瀬 知宏, 宮原 良二, 大宮 直木, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 1228-1228 2012年4月  
  • 松崎 一平, 宮原 良二, 後藤 秀実, 舩坂 好平, 古川 和宏, 坂巻 慶一, 立松 英純, 鶴留 一誠, 山本 富美子, 大野 栄三郎, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 渡辺 修, 前田 修, 安藤 貴文
    Gastroenterological Endoscopy 54(Suppl.1) 1248-1248 2012年4月  
  • 山本 富美子, 宮原 良二, 舩坂 好平, 古川 和宏, 坂巻 慶一, 立松 英純, 鶴留 一誠, 松崎 一平, 大野 栄三郎, 川嶋 啓揮, 伊藤 彰浩, 大宮 直木, 廣岡 芳樹, 前田 修, 渡辺 修, 安藤 貴文, 後藤 秀実
    Gastroenterological Endoscopy 54(Suppl.1) 1261-1261 2012年4月  
  • Kazuhiro Furukawa, Ryoji Miyahara, Kohei Funasaka, Keiichi Sakamaki, Hidezumi Tatematsu, Issei Tsurudome, Fumiko Yamamoto, Ippei Matsuzaki, Eizaburo Ohno, Hiroki Kawashima, Akihiro Itoh, Naoki Ohmiya, Yoshiki Hirooka, Osamu Watanabe, Osamu Maeda, Takafumi Ando, Hidemi Goto
    GASTROINTESTINAL ENDOSCOPY 75(4) 237-238 2012年4月  

書籍等出版物

 46
もっとみる

講演・口頭発表等

 430
もっとみる

担当経験のある科目(授業)

 7
もっとみる

所属学協会

 12
もっとみる

共同研究・競争的資金等の研究課題

 31
もっとみる

産業財産権

 1

メディア報道

 32
もっとみる
一覧へ戻る